4. General Drug InformationGeneral Drug Information
Indication and Dose AdministrationIndication and Dose Administration
Bicalutamide is a treatment for Stage D2
Metastatic Carcinoma of the Prostate
Bicalutamide is recommended dose is 50 mg once dailyBicalutamide is recommended dose is 50 mg once daily
with or without food in the same time (morning or evening)
Bicalutamide is indicated for use in combination therapy
with LHRH-analog
Note: 150 mg once daily is not approved in The US
5. General Drug InformationGeneral Drug Information
Monitoring Patient’s ResponseMonitoring Patient’s Response
Measuring Prostate Specific Antigen (PSA)
Every month for the first 4 month
Periodically thereafterPeriodically thereafter
9. General Drug InformationGeneral Drug Information
Complete Androgen BlockadeComplete Androgen Blockade
Efficacy BenefitEfficacy Benefit
Bicalutamide
= 0.93
Flutamide
= 0.93
10. Bicalutamide
= 0.87
General Drug InformationGeneral Drug Information
Complete Androgen BlockadeComplete Androgen Blockade
Efficacy BenefitEfficacy Benefit
Flutamide
= 0.87
11. General Drug InformationGeneral Drug Information
Complete Androgen BlockadeComplete Androgen Blockade
Tolerability BenefitTolerability Benefit
N=830
Bicalutamide 50 mg 1x1
Flutamide 250 mg 1x3
Goserline 3.6 mg/28d
Lueprolide 7.5 mg mg/28d
plus
Goserline 3.6 mg/28d
Lueprolide 7.5 mg mg/28d
plus
1:1
2:1
2:1
13. Study Conclusion
General Drug InformationGeneral Drug Information
Complete Androgen BlockadeComplete Androgen Blockade
Efficacy+TolerabilityEfficacy+Tolerability BenefitBenefit
24. …Prescribing the Trusted Treatment ……Prescribing the Trusted Treatment …
with Thewith The WorldclassWorldclass Standard ProductStandard Productwith Thewith The WorldclassWorldclass Standard ProductStandard Product
by Youby You
